Fibrin and D-dimer bind to monomeric GPVI by Onselaer, M-B et al.
REGULAR ARTICLE
Fibrin and D-dimer bind to monomeric GPVI
Marie-Blanche Onselaer,1 Alexander T. Hardy,1 Clare Wilson,2 Ximena Sanchez,3 Amir K. Babar,4 Jeanette L. C. Miller,4 Callum N. Watson,1
Stephanie K. Watson,1 Arkadiusz Bonna,5 Helen Philippou,2 Andrew B. Herr,4 Diego Mezzano,3 Robert A. S. Arie¨ns,2 and Steve P. Watson1
1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; 2Thrombosis and Tissue Repair
Group, Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom; 3Laboratorio de Hemostasia, Pontificia Universidad Catolica de Chile,
Santiago, Chile; 4Division of Immunobiology, Center for Systems Immunology, and Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH; and 5Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom
Key Points
•GPVI is the major
signaling receptor for
fibrin in human plate-
lets; the GPVI binding
site is located in the
fibrin D-dimer region.
•D-dimer blocks platelet
aggregation by fibrin
and collagen but not by
a collagen-related pep-
tide, suggesting a dis-
tinct binding epitope.
Fibrin has recently been shown to activate platelets through the immunoglobulin receptor
glycoprotein VI (GPVI). In the present study, we show that spreading of human platelets on
ﬁbrin is abolished in patients deﬁcient in GPVI, conﬁrming that ﬁbrin activates human
platelets through the immunoglobulin receptor. Using a series of proteolytic fragments, we
show that D-dimer, but not the E fragment of ﬁbrin, binds to GPVI and that immobilized
D-dimer induces platelet spreading through activation of Src and Syk tyrosine kinases. In
contrast, when platelets are activated in suspension, soluble D-dimer inhibits platelet
aggregation inducedbyﬁbrin and collagen, but not bya collagen-related peptide composedof
a repeat GPO sequence or by thrombin. Using surface plasmon resonance, we demonstrate
that ﬁbrin binds selectively to monomeric GPVI with a KD of 302 nM, in contrast to collagen,
which binds primarily to dimeric GPVI. These results establish GPVI as the major
signaling receptor for ﬁbrin in human platelets and provide evidence that ﬁbrin binds to
a distinct conﬁguration of GPVI. This indicates that it may be possible to develop agents
that selectively block the interaction of ﬁbrin but not collagen with the immunoglobulin
receptor. Such agents are required to establish whether selective targeting of either
interaction has the potential to lead to development of an antithrombotic agent with a
reduced effect on bleeding relative to current antiplatelet drugs.
Introduction
Until recently, glycoprotein VI (GPVI) was thought to function only as the principal signaling receptor in
platelets for collagen, with a critical role in the initiation of thrombus formation at sites of damage to the
vessel wall. However, the recent discovery that fibrin, the final product of the coagulation cascade,
activates GPVI suggests that the immunoglobulin receptor plays a critical role in thrombus
propagation.1,2 This provides an explanation for the paradoxical observation that mice deficient in
GPVI fail to form an occlusive thrombus in a FeCl3 injury model, even though the onset of thrombosis,
which is where collagen is exposed, is not altered.3 Given the relatively mild bleeding diathesis of mice
and patients deficient in GPVI,1,4,5 these findings raise the possibility that activation of GPVI by fibrin
represents a target for development of a new class of antithrombotic drug that may have a reduced
effect on bleeding relative to current antiplatelet drugs.
Fibrinogen plays a critical role in thrombus formation through the formation of a fibrin clot and by
contributing to platelet aggregation via interaction with integrin aIIbb3. Fibrinogen has a molecular
weight of 340 kDa and is composed of 2 repeats of 3 polypeptides consisting of Aa, Bb, and g chains.
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Fibrin is an insoluble polymer that is generated from fibrinogen by
the proteolytic action of thrombin. Thrombin cleaves fibrinogen at 2
distinct sites in the central E domain of fibrinogen, situated at the
N-termini of the a chain and the b chain, releasing fibrinopeptides
A and B, respectively. Proteolytic cleavage induces conformational
changes that lead to formation of fibrin monomers and exposure of
new N-termini,6 which interact with a constitutive complementary
binding pocket in the D-domain in the g and b chains, respectively,
leading to protofibril formation through D-E-D interactions.7
Fibrinopeptide B cleavage is associated with release of the a
C-terminal domains, which leads to lateral aggregation of proto-
fibrils, increasing fibrin fiber thickness.8 Thrombin also activates
FXIII, which catalyzes the formation of g-g and a-a isopeptide
bonds, thereby stabilizing the clot and improving resistance to
fibrinolysis.9 Lysis of crosslinked fibrin by plasmin produces D-dimer
containing g-g crosslinks that hold 2 D-regions together.
In this study, we have mapped the binding sites between fibrin and
GPVI by investigating the action of plasmin-derived proteolytic
fragments of fibrin on platelet activation. Using this approach, we
have localized the binding site of GPVI to the D-dimer region
in fibrin. We show that immobilized D-dimer induces platelet
spreading, whereas soluble D-dimer inhibits collagen- and fibrin-
induced platelet activation. Further, we provide evidence that the 2
ligands bind to distinct configurations of GPVI and possibly to
distinct epitopes, suggesting that it may be possible to generate
inhibitors that selectively inhibit binding of collagen or fibrin.
Materials and methods
Reagents
Human, mice, and bovine fibrinogens were from Enzyme Research
Laboratories (Swansea, United Kingdom). Goat anti-human immu-
noglobulin G (IgG) HRP conjugated was from ThermoFisher
Scientific (Glasgow, United Kingdom). Rabbit anti-6-His HRP
conjugated (Bethyl A190-114P) and PPACK were from Cambridge
Bioscience (Cambridge, United Kingdom). Alexa-488 phalloidin was
from Molecular Probes (Life Technologies, Paisley, United Kingdom).
Collagen and collagen diluent were from Nicomed. Collagen-related
peptide (CRP; 10 glycine-proline-hydroxproline [GPO] repeats) was
crosslinked as described.10 PAR-1 peptide (TFLLR) was produced
by Alta Bioscience (Birmingham, United Kingdom). The fibrin
fragment E and D-dimer were from Quadratech (Epsom, United
Kingdom). FXIIIa was from Zedira (Darmstadt, Germany). Dasatanib
was from LC Laboratories (Woburn, MA). PRT-060318 was from
Caltag Medsystems (Buckingham, United Kingdom). Recombinant
fibrinogen with gA/gA or g’/g’ domains was generated as de-
scribed.11 gA/g’ fibrinogen was purified from human placenta as
described.12 Revacept was provided by advanceCOR (Munich,
Germany). All other reagents were purchased from Sigma-
Aldrich (Poole, United Kingdom) or described sources.1
Generation of fibrin
Fibrin was freshly prepared in solution by incubating fibrinogen
(1 mg/mL; 4.17 mM) with 1 unit per mL of thrombin and 0.7 mg/mL
of FXIIIa in phosphate-buffered saline (PBS) with 10 mM Ca21 for
1 hour at room temperature. Thrombin was blocked by addition of
PPACK (20 mM) for 15 minutes at room temperature. The fibrin
fiber was sonicated on ice to aid dispersal and concentrated
by centrifugation and resuspension in Tyrode’s N-2-hydroxyethylpi-
perazine-N9-2-ethanesulfonic acid (HEPES) buffer. Fibrin was
generated on coverslips and precoated with fibrinogen, using
thrombin and neutralization by PPACK as described previously.1
GPVI constructions
Soluble GPVI collagen-binding domain (CBD; comprising residues
S2-T183) was prepared as follows. GPVI-Fca13 was used as a
template to amplify the GPVI CBD by polymerase chain reaction. A
forward primer 59-GGAGACCCAAGCTTGCGGCCGCCACCA
TGAAGTTATGGCTGAAT-3 containing an HindIII sequence and
the rat IgG2b secretion signal were used with 59-GCTGCTGAA
TTCCTAGTGGTGGTGGTGGTGGTGGCTACCCTGGAAATAC
AGGTTCTCGGA-39 as the reverse primer, adding a tobacco etch
virus protease–cleavable hexahistidine tag at the C-terminus.
This polymerase chain reaction product was then inserted into the
eukaryotic expression vector pEE12.4 (Lonza Biologics) by HindIII/
EcoRI restriction endonuclease digestion followed by ligation with
T4 DNA ligase.
GPVI-Fcg was prepared by subcloning the GPVI CBD into the
SigpIg1 mammalian expression vector (R&D) that encodes an
N-terminal CD33 signal sequence and a C-terminal human IgG1-Fc
sequence relative to the insert.14,15 Proteins were expressed by
transient transfection of HEK293T cells. Cell-culture medium
containing GPVI CBD or GPVI-Fcg was purified by Ni-NTA or
protein-A affinity chromatography, respectively. Eluted proteins
were further purified by gel filtration using Superdex S75 or S200
columns for GPVI CBD or GPVI-Fcg, respectively.
Revacept was cloned and expressed in Chinese hamster ovary cells
by fermentation in large scale under good manufacturing practice
conditions as described.16
Human platelets
Blood was taken using 3.8% sodium citrate (volume/volume
ratio of 1:9) as the anticoagulant. Informed consent was obtained
according to the guidelines of the local ethics committee. All steps
of this study complied with the ethical principles according to
the Declaration of Helsinki. Washed platelets were obtained by
centrifugation using prostacyclin (2.8 mM) and resuspended in
modified Tyrode’s HEPES buffer (134 mM of NaCl, 0.34 mM of
Na2HPO4, 2.9 mM of KCl, 12 mM of NaHCO3, 20 mM of HEPES,
5 mM of glucose, 1 mM of MgCl2; pH7.3) as described.
1 Platelets
were used at 20 3 109/L for static adhesion or 500 3 109/L for
other studies.
Mice platelets
Gp62/2mice were provided by Jerry Ware (University of Arkansas for
Medical Sciences, Little Rock, AR).17 Wild-type mice were generated
from breeding of heterozygotes or purchased from Harlan Laborato-
ries (Hillcrest, United Kingdom). All procedures were undertaken with
UK HomeOffice approval. Blood was drawn from narcosed and CO2-
asphyxiated mice into 10% acid citrate dextrose and platelet-rich
plasma generated as described.1 Washed platelets were obtained by
centrifugation using prostacyclin (2.8 mM) and resuspended in
modified Tyrode’s HEPES buffer. Platelets were used at 20 3 109/L
for static adhesion or 500 3 109/L for other studies.
Protein phosphorylation
Washed platelets were stimulated with different agonists. Activation
was terminated with ice-cold lysis buffer (300 mM of NaCl, 20 mM
of Tris, 2 mM of EGTA, 2 mM of EDTA, and 2% IGEPALCA-630
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[pH 7.4], plus 2.5 mM of Na3VO4, 100 mg/mL of AEBSF, 5 mg/mL
of leupeptin, 5 mg/mL of aprotinin, and 0.5 mg/mL of pepstatin).
Whole-cell lysates were prepared by boiling a sample of lysate with
sodium dodecyl sulfate (SDS) sample buffer. Syk was immunopre-
cipitated with a-Syk antibody and protein A-Sepharose beads for
2 hours. The beads were then washed, and proteins were eluted by
boiling in SDS sample buffer. Samples were separated by SDS-
polyacrylamide gel electrophoresis, electrotransferred, and western
blotted before exposure to film.
Platelet aggregation
Washed platelets were incubated in the presence of dasatinib (3 mM)
and PRT-060318 (10 mM), D-dimer (30 mg/mL; 1.67 3 1027 M), or
solvent controls. Platelets were stimulated by fibrin, collagen, CRP, or
PAR1. Light transmission was recorded at 37°C with stirring
(1200 rpm) in an aggregometer (Chrono-Log Stago, Parsippany, NJ).
ATP secretion wasmonitored in washed platelets in parallel with platelet
aggregation by adding firefly luciferase and luciferin (Chrono-Lume;
Chrono-Log Stago) and comparing the luminescence generated by
platelet ATP release with an ATP standard.18
Platelet spreading
Glass coverslips were coated in the presence of 10 ug/mL of
collagen, fibrinogen, D-dimer, or fibrin generated as described in the
previous paragraph. After washing with PBS, coverslips were blocked
with 5 mg/mL of heat-inactivated bovine serum albumin in PBS for
60 minutes. Human or mice platelets were allowed to spread for 30 or
45 minutes, respectively, at 37°C before washing with PBS followed
by fixation with paraformaldehyde (3.7%) for 10 minutes. For actin
staining, platelets were permeabilized with 0.1% Triton X-100 for 5
minutes and stainedwith Alex-488-phalloidin for 45minutes in the dark.
Platelets were imaged on a Zeiss Axiovert 200M microscope. Platelet
surface area was analyzed using ImageJ (National Institutes of Health,
Bethesda, MD). In each independent experiment, 5 random pictures
were analyzed (100 platelets in total).
Solid-phase binding assay
Two recombinant proteins were used in the binding studies: GPVI-
Fc fusion (dimer) and GPVI-His tagged (monomer). Coverslips
were coated with collagen, fibrinogen, fibrin, and fibrin fragments
(10 mg/mL) overnight at 4°C. The plates were blocked with 3%
bovine serum albumin–PBS for 1 hour, washed, and incubated with
monomeric or dimeric GPVI (100 nM) for 1 hour. After washing,
secondary antibodies HRP-conjugated goat anti-human IgG-Fc or
HRP-conjugated anti-His Tag were added at 4 mg/mL for 1 hour to
detect GPVI dimers or monomers, respectively. The binding of GPVI
to the immobilized substrate was visualized using 3,39,5,59-
tetramethylbenzidine. The reaction was stopped by addition of
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Figure 1. GPVI-deficient patients are unresponsive to fibrin. Glass coverslips were coated with collagen or fibrin as described in "Materials and methods." (Ai) Human
platelets (ptl; 20 3 109/L) were allowed to spread on coated coverslips, followed by staining of actin with Alexa-488 phalloidin. The pictures are representative results of a control
and 2 GPVI-deficient patients. Scale bar, 5 mm. (Aii) The histograms illustrate the quantification of the surface area of platelets and the number of platelets calculated per millimeter
squared. In each independent experiment, 5 random pictures were analyzed (100 platelets in total). The results are shown as mean 6 standard deviation. ***P , .001.
(B) Representative aggregation traces form a GPVI-deficient patient are shown (the control aggregation trace is representative of .20 donors).
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H2SO4 (2 M), and absorbance was measured at 450 nm with a
spectrofluorometer. For the competitive binding assay, monomeric
GPVI was incubated with a different concentration of D-dimer for
1 hour before addition to the immobilized substrate.
SPR
Surface plasmon resonance (SPR) ligands and analytes were
prepared as detailed in supplemental Materials. SPR was
performed on a Pioneer platform from PALL Forte´Bio (Portsmouth,
United Kingdom) using a OneStep titration function based on Taylor
dispersion injection theory.19,20 All kinetic binding assays were
performed with both the analysis and sample rack temperatures at
37°C. GPVI analytes were diluted to 1 mM using the same batch of
running buffer for the blanks and the OneStep titration function. The
GPVI analytes were injected into the sensor chamber at a flow rate
of 30 mL per minute using the OneStep titration function with a loop
inject of 100% after 8 leadoff blanks and 3 bulk standard injects of
3% sucrose in running buffer for n 5 3 (3 replicates/cycles) using
group replicates. The GPVI analytes had a dissociation time of 400
seconds, and the chip surface was regenerated with 1 M of NaCl
with a flow rate of 60 mL per minute for 10 seconds followed by a
400-second dissociation period. One periodic blank was performed
every 3 cycles. The binding data were zeroed to the preinject
resonance units to obtain a starting response unit of 0, the reference
curve was subtracted, and the data were blanked to the closest buffer
blank. Data were analyzed with Qdat data analysis software (PALL
Forte´Bio). Binding data were fit using a simple KA/KD model, and
aggregation/retention parameters were adjusted per binding curve
according to goodness of fit and curve type.
Data analysis
Statistical analysis was realized by ANOVA with Tukey posttest.
Results are shown as the mean 6 standard deviation of a minimum
of 3 experiments.
Results
Fibrin does not activate GPVI-deficient
human platelets
We have shown that fibrin binds to human and mouse GPVI and
that spreading of mouse platelets on fibrin is abolished in the
absence of GPVI.1 In the present study, we have investigated
spreading in human platelets deficient in GPVI through access to 2
unrelated patients who do not express the immunoglobulin receptor
(Figure 1A). The 2 patients are homozygous for an adenine insertion
in exon 6 at position 242, which generates a stop codon before the
transmembrane domain and therefore prevents surface expression
of GPVI.4 Platelets from either patient do not aggregate to collagen
and do not express detectable GPVI when measured by flow
cytometry (Figure 1B; data not shown).
Platelets from healthy controls generate filopodia and full
lamellipodia sheets on fibrin as shown in Figure 1A and
previously reported.1,2 A similar pattern of spreading is seen in
platelets from donors who are heterozygous for the mutation
A
Fibrin
Dasat
PRT
Control60s
10%
0
Fibrin
PRT
Dasat
135
100
80
58
46
32
25
80
WB: -Tubulin
WB: 4G10
WB: 4G10
WB: Syk
IP: Syk
80
- - -
- - --
- -
- -+
+
+
+
- - +
C
B
60
40
20
0
Control Dasatinib PRT
**
Ag
gr
eg
at
ion
 (%
)
**
Figure 2. Fibrin induces Syk-dependent platelet activation and aggregation. (A) Platelets (500 3 109/L), pretreated where indicated with dasatinib (dasat; 3 mM) or
PRT-060318 (10 mM), were stimulated with fibrin dispersed as a suspension. (B) The histogram represents 3 independent experiments. The results are shown as mean6 standard
deviation. **P , .01. (C) Stimulations were stopped with addition of 23 lysis buffer. A sample of the whole-cell lysate (WCL) was removed, and the remaining lysate was used
to immunoprecipitate (IP) Syk. WCLs and IPs were separated by SDS-polyacrylamide gel electrophoresis and western blotted (WB) for pTyr and Syk. The results are shown as
a representative of 3 independent experiments.
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(data not shown). In contrast, spreading on fibrin is markedly
inhibited in platelets from patients who lack the glycoprotein
receptor, with only a small number of platelets showing partial or
in rare cases full spreading (Figure 1A). In addition, adhesion of
platelets to fibrin is reduced by ;40% in both patients
(Figure 1Aii). These results demonstrate that spreading of
human platelets on fibrin is critically dependent on GPVI but
that platelets express additional receptors for fibrin that support
adhesion, such as integrin aIIbb3.21
To further investigate GPVI as a signaling receptor for fibrin, we
generated a suspension of fibrin and monitored aggregation of
washed platelets. This approach is analogous to the generation of
a suspension of collagen. Fibrin was generated from fibrinogen by
addition of thrombin and, after neutralization of the protease,
dispersed by sonication. Platelets underwent a slow aggregation
to fibrin, which varied between donors and fibrin preparations as
illustrated in Figures 1B and 2A. Aggregation was not preceded
by a clear increase in optical density, which is indicative of shape
change, possibly because it was masked by the relatively slow
onset of response. Aggregation was abolished in the absence of
GPVI or in the presence of the Src and Syk inhibitors dasatinib
(3 mM)and PRT-060318 (10 mM), respectively (Figure 2A-B).
Additionally, dasatinib and PRT-060318 blocked the increase in
tyrosine phosphorylation in whole-cell lysates and Syk immuno-
precipitates in response to fibrin (Figure 2C). These observations
demonstrate that fibrin activates platelets through GPVI and Src
and Syk tyrosine kinases.
Fibrin binds to monomeric GPVI
GPVI is expressed on platelets primarily as a monomer and forms
dimers and higher oligomers upon activation by collagen and other
agonists.22,23 Collagen binds with high affinity to dimeric but not to
monomeric GPVI, with conversion of monomers to dimers being a
key step in collagen-mediated platelet activation.19,24 In the present
study, we measured binding of monomeric and dimeric GPVI to
immobilized fibrin using SPR. Monomeric GPVI binds to fibrin with a
KD of 3026 5 nM (Figure 3A), but there was no detectable binding
of GPVI at a concentration of 1 mM (data not shown). Selectivity
was confirmed in a solid-phase binding assay, whereas collagen
bound preferentially to dimeric GPVI (Figure 3B) as reported.24 In
line with this, Revacept, a dimeric form of GPVI in a phase II clinical
trial, did not bind to fibrin (Figure 3C). These results show that fibrin
and collagen bind selectively to monomeric and dimeric GPVI,
respectively.
Mapping of the GPVI binding site in fibrin
Fibrin(ogen) shows a high level of sequence identity among
species. Consistent with this, we observed a similar level of binding
of GPVI to fibrin derived from human, murine, and bovine fibrinogen
(supplemental Figure 1A), indicating that the binding site for GPVI is
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conserved. Fibrinogen exists in 2 splicing variants in the g-chain
region, which give rise to 3 possible combinations: gA/gA,
gA/g’, and g’/g’. The g’ chain has a 20–amino acid insertion in its
C-terminus, which replaces the last 4 amino acids in the gA
chain. No observable difference in the binding of monomeric
GPVI to the 3 gA/g’ combinations was detected (supplemental
Figure 1B), showing that splicing does not affect binding of fibrin
to GPVI.
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Figure 5. D-dimer–induced spreading is dependent on
GPVI signaling. (A) Glass coverslips were coated overnight
with D-dimer as described in "Materials and methods." Human
platelets (ptl; 20 3 109/L) were preincubated with dasatinib
(3 mM), PRT-060318 (10 mM), or vehicle before being allowed to
spread on coated coverslips. Actin staining was performed on
fixed platelets with Alexa-488 phalloidin. Scale bar, 5 mm. The
figure is representative of 3 similar experiments. (B) Quantifica-
tion of platelet surface area and platelet count per millimeter
squared (n 5 3). In each independent experiment, 5 random
pictures were analyzed (100 platelets in total). The results are
shown as mean 6 standard deviation. *P , .05, ***P , .001
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To further map the site of interaction in fibrin, we investigated
binding of proteolytic fragments of fibrin. Using a solid-phase
binding assay, we observed a similar level of binding of monomeric
GPVI to immobilized fibrin and to D-dimer, but not to E fragment,
indicating that the binding epitope in fibrin resides in the D region or
the D-D interface (Figure 3D). Neither dimeric GPVI nor Revacept
was able to bind to the D-dimer or E fragment of fibrin, consistent
with the absence of binding to fibrin (Figure 3C; data not shown).
Immobilized D-dimer induces spreading of platelets
via GPVI
The observation that D-dimer binds to GPVI prompted investigation of
whether it induces spreading of mouse and human platelets when
immobilized on a surface. As shown in Figure 4A, D-dimer stimulates a
similar pattern of spreading of mouse platelets to that induced by fibrin.
In contrast, there was no spreading on fibrinogen as previously
reported.1 Spreading on D-dimer and fibrin was abolished in GPVI-
deficient mouse platelets, and adhesion was reduced by ;50% in
both cases (Figure 4B). Adhesion and spreading on fibrin and D-dimer
were markedly inhibited or abolished in the presence of the aIIbb3
antagonist eptifibatide (supplemental Figure 2).
Spreading of human platelets on D-dimer is blocked in the presence of
the inhibitors of Src and Syk inhibitors, dasatinib and PRT-060318,
respectively (Figure 5). Both inhibitors also reduce adhesion by the
same extent as that seen with fibrin (Figure 5). Spreading and adhesion
are also blocked or markedly reduced in the presence of the aIIbb3
antagonist eptifibatide but are not altered in the presence of
monoclonal antibody (mAb) IV.3, which blocks FcgRIIA (supplemental
Figure 3). Spreading of human platelets on fibrin was partially reduced
in the presence of apyrase and indomethacin (data not shown).
Immobilized fibrin and D-dimer stimulated tyrosine phosphorylation in
whole-cell lysates, with the response to fibrin being similar to that of
collagen (supplemental Figure 4).
Soluble D-dimer inhibits spreading and aggregation
of human platelets induced by fibrin and collagen
Although, when immobilized, D-dimer stimulates spreading of platelets,
it does not induce aggregation or secretion in platelet suspensions at
concentrations up to 100mg/mL or binding of annexin-V (procoagulant
activity) or mAb PAC-1 (aIIbb3 activation; data not shown). In contrast,
D-dimer (100 mg/mL) inhibits adhesion and spreading of human
platelets on collagen- and fibrin-coated surfaces, with an EC50 value in
the order of 250 nM (50 mg/mL) for both ligands (Figure 6A-B).
D-dimer (10-100 mg/mL) also inhibits aggregation and secretion in
washed platelets induced by collagen (0.1-0.3 mg/mL), with full
recovery at higher concentrations (Figure 7A; supplemental Figure 5),
but not to a PAR1 receptor–activating peptide or to CRP consisting of
GPO repeats (Figure 7B). As expected, D-dimer blocks aggregation
induced by fibrin (Figure 7Bii). A similar inhibitory effect of D-dimer
against collagen but not CRP was seen in platelet-rich plasma
(supplemental Figure 6). These results demonstrate that the epitope
for D-dimer overlaps with that for fibrin (as expected) and possibly with
that for collagen but not that for CRP.
Discussion
The present study reports several new observations on the
interaction of GPVI with fibrin. Firstly, we demonstrate that GPVI
is the major signaling receptor for fibrin in human platelets, using
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Alexa-488 phalloidin. Scale bar, 5 mm. (Aii) Quantification of
the surface area of platelets and the number of platelets per
millimeter squared of 3 independent experiments. In each
independent experiment, 5 random pictures were analyzed
(100 platelets in total). The results are shown as mean 6
standard deviation (SD). *P , .05, **P , .01. (B) The graph
represents the competition binding assay between monomeric
GPVI (100 nM) and D-dimer on collagen- or fibrin-coated
surfaces. Binding in the absence of D-dimer is represented as
100%. The results are shown as mean 6 SD and are
representative of 3 experiments. **P , .01, ***P , .001.
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platelets from patients who lack GPVI. This supports previous
observations with the anti-GPVI blocking mAb 9012 and shows that
its inhibitory effect is not due to steric hindrance.2 Secondly, the
retention of adhesion to immobilized fibrin in GPVI-deficient platelets
and the inhibitory effect of eptifibatide confirm integrin aIIbb3 as a
fibrin receptor, indicating that it may underlie the limited spreading in
GPVI-deficient platelets.21 Thirdly, we show that fibrin binds
selectively to monomeric GPVI, in contrast to collagen, which binds
to dimeric GPVI. The interconversion of GPVI between monomeric
and dimeric forms will therefore govern the interaction with collagen
and fibrin, with nonactivated platelets, which express predominately
monomeric GPVI, binding selectively to fibrin.22,23 The polymeric
nature of fibrin can support binding to several GPVI receptors and in
this way lead to activation. Fourthly, we show that fibrin recognizes
GPVI through its D-dimer region and that D-dimer blocks activation
by collagen and fibrin in suspension, suggesting a shared motif or
closely located site of interaction. Alternatively, D-dimer may inhibit
the response to collagen by preventing formation of GPVI dimers.
Fifthly, the observation that D-dimer has no effect on platelet
activation by CRP indicates that collagen and fibrin may bind to
distinct epitopes in GPVI and that it may be possible to develop
agents that selectively block binding of 1 or the other ligand. Such
agents are required to determine the role of GPVI in platelet activation
by collagen and fibrin in hemostasis and thrombosis.
Cocrystallization studies will be crucial in determining the degree to
which the binding sites for fibrin and collagen overlap. Knowledge of
the structure of GPVI, along with mutagenesis studies, predicts that
CRP binds to a groove in the D1-domain of the immunoglobulin
receptor.25 The spacing and orientation of the groove match the
spacing and orientation of triple helices in collagen, suggesting a
plausible mechanism by which dimeric GPVI recognizes collagen.
There are, however, a number of unresolved questions regarding
the interaction, because mutations at the distal end of D1 (far from
the proposed binding groove) diminish binding of CRP or
collagen.26,27 Furthermore, mutagenesis and NMRmapping studies
show an analogous distal site of D1 for collagen in LAIR-1, a related
immunoglobulin collagen receptor.28 The site of interaction of fibrin
with GPVI is not yet known.
D-dimer levels are elevated in patients who have experienced
trauma, cancer, or thromboembolism.29 The peak concentrations
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Figure 7. D-dimer inhibits platelet activation by collagen and fibrin in washed platelets. Platelets (500 3 109/L) in the presence of D-dimer (30 mg/mL) were stimulated
with collagen (Ai-ii) or CRP, PAR1-peptide, or fibrin (Bi-ii). Aggregation and secretion were monitored by lumiaggregometry (Chrono-Log). The figures show representative
aggregation traces with histograms summarizing 3 independent experiments. The results are shown as mean 6 standard deviation. *P , .05, **P , .01, ***P , .001.
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are in the order of 50 mg/mL,30-34 which is sufficient to induce only
weak inhibition of aggregation and secretion to low concentrations
of collagen. This inhibitory effect is readily overcome by moderate
increases in the collagen concentration. Thus, the physiological and
pathological significance of D-dimer binding to GPVI in patients is
likely to be minimal.
We have previously reported that the generation of an occlusive
thrombus in an FeCl3 injury model is blocked in GPVI-deficient mice,
whereas the onset of thrombosis, where collagen is exposed, is not
altered.3 This suggests that the binding of fibrin to GPVI plays a
critical role in formation of an occlusive thrombosis. The develop-
ment of an inhibitor that selectively blocks activation by fibrin but not
collagen is required to confirm this. Revacept, a recombinant dimer
form of GPVI that inhibits thrombosis but not hemostasis in mouse
models is in a phase II clinical trial for prevention of ischemic
complications in patients with symptomatic carotid artery steno-
sis.16 As a dimer of GPVI, Revacept blocks the interaction of GPVI
with collagen but not with fibrin.
Mice and patients deficient in GPVI have a mild bleeding diathesis.
The 2 GPVI-deficient patients in this study are from unrelated
families in Chile and are homozygous for the same mutation.
Although both index cases were discovered because of a bleeding
diathesis, their bleeding is mild, and it is unclear whether the
bleeding is due to a coinherited or acquired defect. The discovery of
additional patients deficient in GPVI is required to provide a more
complete understanding of the role of the glycoprotein receptor in
hemostasis and thrombosis.
In summary, the present study confirms GPVI as the major
signaling receptor for fibrin in human platelets and demon-
strates that binding occurs selectively to monomeric GPVI and
through the D-dimer region of fibrin. This suggests that it may be
possible to develop inhibitors that selectively block platelet
activation by fibrin. Such inhibitors can be used to establish the
contribution of GPVI activation by fibrin to thrombosis and may
represent a new class of antiplatelet agent with a minimal effect
on hemostasis given the mild bleeding diathesis of GPVI-
deficient patients.
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